Quigley plans additional studies of QR-435 for ocular herpes

By Lisa Kerner

Erie, Pa., May 22 - Quigley Pharma Inc., a wholly owned subsidiary of The Quigley Corp., said it plans a series of animal studies to evaluate the antiviral efficacy and toxicity of its naturally derived topical compound QR-435 for ocular herpes at The Campbell Ophthalmic Microbiology Laboratory at the University of Pittsburgh.

Herpes simplex virus type 1 (HSV-1) is the leading cause of infectious corneal blindness in industrialized nations, with about 400,000 cases in the United States annually, according to a company news release.

"Treatments for HSV-1 that are currently available are over 20 years old and are associated with safety issues," chief operating officer and executive vice president Richard Rosenbloom said in the release.

"The development of a new, effective, non-toxic topical antiviral would present a significant improvement and much needed treatment."

Previous studies of QR-435 demonstrated reproducible potent direct antiviral activity against an ocular isolate of HSV-1 as well as similar potent direct antiviral activity against a second similar ocular isolate of HSV-1 and multiple clinical genital isolates of HSV-2.

Quigley plans to also continue testing the QR-435 compound to determine its efficacy against genital herpes.

The Quigley Corp. is a natural health medical science company located in Doylestown, Pa.

Quigley Pharma Inc. researches and commercializes patented botanical and naturally derived prescription drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.